Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...

The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...

Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...

The FDA approved esketamine (Spravato) nasal spray as monotherapy for adults with treatment-resistant depression who had an ...

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...

Scientific Research on Ketamine Psychiatric Treatment While it is easy to see ... Why was the FDA approval of esketamine so controversial among many researchers? Researchers Mark Horowitz and ...

Once sidelined in the 1970s, psychedelic substances—ranging from esketamine (a ketamine derivative ... while the other receives a placebo or standard treatment. To ensure unbiased results ...